These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9812227)

  • 21. Spectrum of genital human papillomavirus infection in a female adolescent population.
    Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
    Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of colposcopy in the screening of pre-malignant and malignant lesions of uterine cervix.
    Chakrabarti RN; Bhattacharya D; Roy NN; Das I
    Eur J Gynaecol Oncol; 1987; 8(6):603-6. PubMed ID: 3691568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Condylomas, cervical dysplasias and carcinoma of the cervix (author's transl)].
    de Brux J; Ionesco M; Cochard B; Masson MF; Kaeding H
    J Gynecol Obstet Biol Reprod (Paris); 1980; 9(6):613-20. PubMed ID: 6257776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies.
    Zhang ZF; Begg CB
    Int J Epidemiol; 1994 Aug; 23(4):682-90. PubMed ID: 8002180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are Papanicolaou smears enough? Acetic acid washes of the cervix as adjunctive therapy: a HARNET study. Harrisburg Area Research Network.
    Slawson DC; Bennett JH; Herman JM
    J Fam Pract; 1992 Sep; 35(3):271-7. PubMed ID: 1517723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of Chlamydia trachomatis infection in a population of asymptomatic women in a screening program for cervical cancer.
    Meijer CJ; Calame JJ; de Windt EJ; Risse EK; Bleker OP; Kenemans P; Quint WG; Meddens MJ
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):127-30. PubMed ID: 2498093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of the model used for screening and early diagnosis of cervical cancer in Karelia].
    Kovchur PI; Bakhidze EV
    Vopr Onkol; 2014; 60(3):298-305. PubMed ID: 25033680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age trends in pre-cancerous and cancerous lesions of the uterine cervix in a cytology screening programme: what should be the target age group for a major thrust of screening in resource-limited settings?
    Gupta S; Sodhani P; Halder K; Chachra KL; Singh V; Sehgal A
    Cytopathology; 2008 Apr; 19(2):106-10. PubMed ID: 17681014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for cervical dysplasia in department of genitourinary medicine.
    Tait IA; Alawattegama AB; Rees E
    Genitourin Med; 1988 Aug; 64(4):255-8. PubMed ID: 3169756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence, pathophysiology and treatment of cervical cancer.
    Dunleavey R
    Nurs Times; 2004 Nov 2-8; 100(44):38-41. PubMed ID: 15552491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study.
    Wang J; Andrae B; Sundström K; Ström P; Ploner A; Elfström KM; Arnheim-Dahlström L; Dillner J; Sparén P
    BMJ; 2016 Feb; 352():i276. PubMed ID: 26869597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective cervical cytology screening: discriminant analysis approach.
    Juneja A; Murthy NS; Sharma S; Shukla DK; Roy M; Das DK
    Neoplasma; 1993; 40(6):401-4. PubMed ID: 8289972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysplasia and early neoplasia of the uterine cervix. A review.
    Briggs RM
    Obstet Gynecol Surv; 1979 Jan; 34(1):70-99. PubMed ID: 375145
    [No Abstract]   [Full Text] [Related]  

  • 34. Incidence and prevalence of preclinical carcinoma of cervix in a British population.
    Parkin DM; Hodgson P; Clayden AD
    Br J Obstet Gynaecol; 1982 Jul; 89(7):564-70. PubMed ID: 7093172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model for quality assessment in cervical cytology used as a screening test.
    Quantin C; Dusserre L; Montaud AM; Mottot C; Feldman JP
    Qual Assur Health Care; 1992 Jun; 4(2):105-13. PubMed ID: 1511144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of cervical screening results in a population at normal risk.
    Karabulut A; Alan T; Ali Ekiz M; Iritaş A; Kesen Z; Yahşi S
    Int J Gynaecol Obstet; 2010 Jul; 110(1):40-2. PubMed ID: 20362986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence of Gardnerella vaginalis, Trichomonas vaginalis and Candida albicans in the cytology clinic at Ibadan, Nigeria.
    Konje JC; Otolorin EO; Ogunniyi JO; Obisesan KA; Ladipo OA
    Afr J Med Med Sci; 1991 Mar; 20(1):29-34. PubMed ID: 1905467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal cervical cytology mass screening interval for cervical cancer.
    Kobayashi D; Takahashi O; Hikosaka C; Okubo T; Fukui T
    Arch Gynecol Obstet; 2013 Mar; 287(3):549-54. PubMed ID: 23053319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cervical epithelial abnormalities in females with and without genital warts.
    Ward KA; Lowry BE; Houston JR; Maw RD
    Int J STD AIDS; 1994; 5(5):380-1. PubMed ID: 7819367
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives.
    Coldman A; Phillips N; Kan L; Matisic J; Benedet L; Towers L
    J Med Screen; 2005; 12(1):7-11. PubMed ID: 15814014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.